U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487168) titled 'Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors' on March 17.
Brief Summary: This single-center, Phase 1 dose-escalation study will evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of pressurized intraperitoneal aerosol chemotherapy with mitomycin C (PIPAC-MMC) for patients with unresectable peritoneal carcinomatosis from gastrointestinal primaries (colorectal, high-grade appendiceal, or small bowel). Up to three PIPAC procedures are planned at 8-week intervals while patients continue 5-fluorouracil/leucovorin (5-FU/LV) between procedures. The trial uses a Bayesian optimal interval (B...